Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cholecystokinin.

M Albus1

  • 1Psychiatric Hospital, University of Munich, GFR.

Progress in Neuro-Psychopharmacology & Biological Psychiatry
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Cholecystokinin (CCK) peptides modulate brain systems and pain but show limited potential for obesity treatment due to tolerance. Their role in neurological diseases remains unclear.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neurocognitive functioning in patients with first-episode schizophrenia: results of a prospective 15-year follow-up study.

European archives of psychiatry and clinical neuroscience·2019
Same author

What can patients do to facilitate shared decision making? A qualitative study of patients with depression or schizophrenia and psychiatrists.

Social psychiatry and psychiatric epidemiology·2015
Same author

Clinical courses of schizophrenia.

Pharmacopsychiatry·2012
Same author

Systems biology and addiction.

Pharmacopsychiatry·2009
Same author

Meta-analysis of 32 genome-wide linkage studies of schizophrenia.

Molecular psychiatry·2009
Same author

Genomewide linkage scan of schizophrenia in a large multicenter pedigree sample using single nucleotide polymorphisms.

Molecular psychiatry·2009
Same journal

Altered dorsal striatal subregional connectivity associated with distinct executive function deficits in first-episode, drug-naïve major depressive disorder: Evidence from functional connectivity and granger causality analysis.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same journal

Chronic pain and stress: unravelling the common neuroinflammatory, immune and endocrine mechanisms for novel therapeutic approaches.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same journal

Predicting anhedonia and negative cognitive processing changes after 8-week SSRIs treatment in depression from individual differential structural covariance network.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same journal

Mapping intrinsic neural timescale alterations in major depressive disorder.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same journal

Probiotics in reducing negative symptoms of schizophrenia: A systematic review and meta-analysis.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same journal

The IL10 rs1800872 polymorphism differentially modulates the relationship between plasma IL-10 levels and cognitive function in methamphetamine use disorder.

Progress in neuro-psychopharmacology & biological psychiatry·2026
See all related articles

Area of Science:

  • Neuroscience
  • Pharmacology
  • Gastroenterology

Background:

  • Cholecystokinin (CCK) peptides are widely distributed in the brain, excluding the cerebellum.
  • CCK peptides are known to modulate key neurotransmitter systems, particularly the dopaminergic system.

Purpose of the Study:

  • To investigate the multifaceted roles of CCK peptides in the central nervous system.
  • To evaluate the therapeutic potential of CCK peptides in conditions like obesity, pain, and schizophrenia.

Main Methods:

  • Review of existing literature on CCK peptide distribution and function.
  • Analysis of studies on CCK's effects on food intake, pain perception, and neurological disorders.

Main Results:

  • CCK peptides are found throughout the brain and act as neuromodulators, especially in the dopaminergic system.

Related Experiment Videos

  • CCK reduces food intake, but tolerance develops with chronic administration, limiting obesity treatment potential.
  • CCK increases pain thresholds and offers relief for certain types of pain, such as colic and ischemic pain.
  • Evidence regarding CCK levels in cerebrospinal fluid and post-mortem brains in psychiatric and neurological diseases is inconsistent.
  • Clinical studies have not demonstrated beneficial effects of CCK peptides in schizophrenia treatment.

    • Conclusions:

    • CCK peptides play significant neuromodulatory roles in the brain.
    • Therapeutic applications for CCK peptides in obesity and schizophrenia appear limited.
    • CCK's effects on pain modulation warrant further investigation for potential clinical use.